Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | MMP7 | P09237 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | MMP12 | P39900 | 1/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | MME | P08473 | 3/20 | 0.63 |
| ▸ | ACE | P12821 | 3/20 | 0.62 |
| ▸ | CPA1 | P15085 | 1/20 | 0.62 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519583 | 1.00 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL2185269 | 1.00 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL28860411 | 1.00 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL27517670 | 1.00 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| Water SCHEMBL29655482 | 0.99 | LTA4H (0.62) | LTA4HMMP2MMP7MMP9MMP12 | |
| Leu-Leu SCHEMBL10364547 | 0.97 | LTA4H (0.68) | LTA4HMMP2MMP7MMP9MMP12 | |
| Urea SCHEMBL28230423 | 0.97 | LTA4H (0.61) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL30051537 | 0.97 | LTA4H (0.61) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL30050978 | 0.96 | LTA4H (0.63) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL30053218 | 0.95 | LTA4H (0.58) | LTA4HMMP2MMP7MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087804-A1 | METHOD FOR PRODUCING SELF-ASSEMBLING DIPEPTIDES | FERTINAGRO BIOTECH, S.L. (ES) | 2026-04-30 | — | — | WO | claimed |
| US-20250368709-A1 | GLP-1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LTD (GB) | 2025-12-04 | — | — | US | claimed |
| US-12441777-B2 | GLP-1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-10-14 | — | — | US | claimed |
| CN-119215104-A | Traditional Chinese medicine extract and application thereof in preparation of cell necrotic apoptosis inhibitor | 河南中医药大学 | 2024-12-31 | — | — | CN | claimed |
| CN-118894900-A | Beta carboline oral small-molecule anti-inflammatory medicament as well as preparation method and application thereof | 首都医科大学 | 2024-11-05 | — | — | CN | claimed |
| EP-4422686-A1 | MAGNETOSTRICTIVE PIEZOELECTRIC NANOASSEMBLY AS CANCER CHEMOTHERAPEUTIC | Grant Demartino Industries LLC (US) | 2024-09-04 | — | — | EP | claimed |
| CN-116804040-B | Carboline oral small molecule anti-inflammatory medicament and preparation method and application thereof | 首都医科大学 | 2024-08-06 | — | — | CN | claimed |
| US-11851694-B1 | High fidelity in vitro transcription | MODERNATX, INC. (US) | 2023-12-26 | — | — | US | claimed |
| CN-116804040-A | Carboline oral small molecule anti-inflammatory medicament and preparation method and application thereof | 首都医科大学 | 2023-09-26 | — | — | CN | claimed |
| US-20230279053-A1 | GLP-1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| CN-1265673-A | Dipeptide compounds for inhibiting leukocyte adhesion mediated by VLA-4 | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368709-A1 | GLP-1 RECEPTOR ANTAGONISTS | GLP1R, GIPR, GCGR | LTA4H 915/4885MMP2 3993/4885MMP7 4120/4885 |
| US-20230279053-A1 | GLP-1 RECEPTOR ANTAGONISTS | GLP1R, GIPR, GCGR | LTA4H 1146/4885MMP2 3777/4885MMP7 3964/4885 |
| US-12441777-B2 | GLP-1 receptor antagonists | GLP1R, GIPR, GPR119 | LTA4H 905/4885MMP2 3955/4885MMP7 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.